Natural Product (NP) Details

General Information of the NP (ID: NP1489)
Name
Tropisetron
Synonyms
tropisetron; 89565-68-4; Tropisetronum; Tropisteron; [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-3-carboxylate; UNII-6I819NIK1W; Novaban; ICS 205930; (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 1H-indole-3-carboxylate; Navoban (TN); ICF 205-930; CHEMBL56564; beta-Tropisetron; 6I819NIK1W; CHEBI:32269; Tropisetron (INN); DSSTox_CID_24137; DSSTox_RID_80108; DSSTox_GSID_44137; 1alphaH,5alphaH-Tropan-3alpha-yl indole-3-carboxylate; 1H-indole-3-carboxylic acid [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] ester; TKT; Lopac-T-104; CAS-89565-68-4; Tropisetron [INN:BAN]; ICS-205930; Tropisetronum [INN-Latin]; NCGC00015984-03; ICS-205-930; SCHEMBL18297; SCHEMBL18298; SCHEMBL18299; GTPL260; ics205-930; SCHEMBL3953452; CHEMBL1289230; DTXSID2044137; SCHEMBL13287285; CHEBI:94647; HMS2090D16; HMS3886M10; HY-B0072; Tox21_110272; BDBM50108392; PDSP1_000776; PDSP2_000764; s5538; ZINC18130447; AKOS015969677; Tox21_110272_1; ZINC100019233; ZINC100023360; CCG-267308; CS-1146; DB11699; 1H-Indole-3-carboxylic acid, 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, endo-; NCGC00015984-01; NCGC00015984-04; NCGC00161414-01; NCGC00161414-03; NCGC00390718-01; H833; C13666; D02130; Q29428; W-5128; AB00698553-07; AB00698553-09; 565T684; BRD-K50866992-003-09-5; BRD-K50866992-003-10-3; Q27166461; 1H-Indole-3-carboxylic acid (1R,5S)-8-methyl-8-azabicyclo[3.2.1]octane-3-yl ester
    Click to Show/Hide
Species Origin Homo sapiens ...     Click to Show/Hide
Homo sapiens
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Disease Pain [ICD-11: MG30-MG3Z] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absporption
Caco-2 Permeability
 -4.908
 
MDCK Permeability
 -4.75
 
PAMPA
 - -
 
HIA
 - - -
 
Distribution
VDss
 0.97
 
PPB
 70.9%
 
BBB
 +++
 
Metabolism
CYP1A2 inhibitor
 +
CYP1A2 substrate
 - - -
CYP2C19 inhibitor
 - - -
CYP2C19 substrate
 +++
CYP2C9 inhibitor
 - - -
CYP2C9 substrate
 +++
CYP2D6 inhibitor
 +++
CYP2D6 substrate
 +++
CYP3A4 inhibitor
 ++
CYP3A4 substrate
 +++
CYP2B6 inhibitor
 - - -
CYP2B6 substrate
 - - -
CYP2C8 inhibitor
 ++
HLM Stability
 +
 
Excretion
CLplasma
 6.728
 
T1/2
 0.886
Toxicity
DILI
 -
 
Rat Oral Acute Toxicity
 +
 
FDAMDD
 ++
 
Respiratory
 ++
 
Human Hepatotoxicity
 ++
 
Ototoxicity
 +
 
Drug-induced Nephrotoxicity
 +
 
Drug-induced Neurotoxicity
 +++
 
Hematotoxicity
 - -
 
Genotoxicity
 -
 
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++). 2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C17H20N2O2
PubChem CID
656665
Canonical SMILES
CN1C2CCC1CC(C2)OC(=O)C3=CNC4=CC=CC=C43
InChI
1S/C17H20N2O2/c1-19-11-6-7-12(19)9-13(8-11)21-17(20)15-10-18-16-5-3-2-4-14(15)16/h2-5,10-13,18H,6-9H2,1H3/t11-,12+,13?
InChIKey
ZNRGQMMCGHDTEI-FUNVUKJBSA-N
CAS Number
CAS 89565-68-4
ChEBI ID
CHEBI:32269
TTD Drug ID
D0K0KH
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Fluvoxamine      Depression     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Biological
                    Regulation		 Down-regulation 5-HT content
                    In-vivo Model Clinical Trial
                    Experimental
                    Result(s)		 This trial showed a significant efficacy for tropisetron over placebo in treatment of obsessive-compulsive disorder symptoms when added to fluvoxamine.
Target and Pathway
Target(s) Serotonin receptor 3A (HTR3A)  Molecule Info  [3]
KEGG Pathway Serotonergic synapse Click to Show/Hide
NetPath Pathway IL2 Signaling Pathway Click to Show/Hide
Panther Pathway 5HT3 type receptor mediated signaling pathway Click to Show/Hide
Reactome Ligand-gated ion channel transport Click to Show/Hide
WikiPathways SIDS Susceptibility Pathways Click to Show/Hide
2 Iron uptake and transport
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 260).
Reference 2 Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial. J Psychopharmacol. 2019 Nov;33(11):1407-1414.
Reference 3 Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
 Download Picture         KEGG Link